MX2014002307A - Metodo para predecir el riesgo de hipertension asociado a la terapia antiangiogenesis. - Google Patents

Metodo para predecir el riesgo de hipertension asociado a la terapia antiangiogenesis.

Info

Publication number
MX2014002307A
MX2014002307A MX2014002307A MX2014002307A MX2014002307A MX 2014002307 A MX2014002307 A MX 2014002307A MX 2014002307 A MX2014002307 A MX 2014002307A MX 2014002307 A MX2014002307 A MX 2014002307A MX 2014002307 A MX2014002307 A MX 2014002307A
Authority
MX
Mexico
Prior art keywords
hypertension associated
gene
angiogenesis
bevacizumab
genotype
Prior art date
Application number
MX2014002307A
Other languages
English (en)
Inventor
Sanne Lysbet De Haas
Paul Delmar
Diether Lambrechts
Stefan Scherer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2014002307A publication Critical patent/MX2014002307A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

La invención se refiere a un método de predicción de la susceptibilidad de un paciente a desarrollar hipertensión asociada a un tratamiento antiangiogénesis, tal como bevacizumab, mediante la determinación del genotipo del gen KDR y/o del gen EGF. La invención se refiere además a una composición farmacéutica que comprende un inhibidor de la angiogénesis, tal como bevacizumab, para el tratamiento de un paciente que sufre de un cáncer, basado en el genotipo del gen KDR y/o EGF. La invención se refiere además a un método para reducir el riesgo de hipertensión asociado a una terapia antiangiogénesis, tal como bevacizumab, en un paciente que sufre de cáncer, mediante la determinación del genotipo del gen KDR y/o del gen EGF.
MX2014002307A 2011-08-31 2012-08-28 Metodo para predecir el riesgo de hipertension asociado a la terapia antiangiogenesis. MX2014002307A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11179500 2011-08-31
PCT/EP2012/066632 WO2013030168A1 (en) 2011-08-31 2012-08-28 Method for predicting risk of hypertension associated with anti-angiogenesis therapy

Publications (1)

Publication Number Publication Date
MX2014002307A true MX2014002307A (es) 2014-08-26

Family

ID=46724461

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002307A MX2014002307A (es) 2011-08-31 2012-08-28 Metodo para predecir el riesgo de hipertension asociado a la terapia antiangiogenesis.

Country Status (16)

Country Link
US (1) US20140294811A1 (es)
EP (2) EP2751280B1 (es)
JP (1) JP2014526901A (es)
KR (1) KR20140064924A (es)
CN (1) CN103946395A (es)
AR (1) AR087714A1 (es)
AU (1) AU2012300986A1 (es)
BR (1) BR112014004763A2 (es)
CA (1) CA2845386A1 (es)
ES (1) ES2589455T3 (es)
IL (1) IL230783A0 (es)
MX (1) MX2014002307A (es)
RU (1) RU2014110270A (es)
SG (1) SG2014008585A (es)
WO (1) WO2013030168A1 (es)
ZA (1) ZA201400950B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021055089A1 (en) * 2019-09-20 2021-03-25 The University Of North Carolina At Chapel Hill Methods of identifying risk of bevacizumab-induced proteinuria and hypertension

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
NO870613L (no) 1986-03-05 1987-09-07 Molecular Diagnostics Inc Deteksjon av mikroorganismer i en prŸve inneholdende nukleinsyre.
US5310893A (en) 1986-03-31 1994-05-10 Hoffmann-La Roche Inc. Method for HLA DP typing
US5604099A (en) 1986-03-13 1997-02-18 Hoffmann-La Roche Inc. Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
US4851331A (en) 1986-05-16 1989-07-25 Allied Corporation Method and kit for polynucleotide assay including primer-dependant DNA polymerase
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
US5310652A (en) 1986-08-22 1994-05-10 Hoffman-La Roche Inc. Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription
US5693517A (en) 1987-06-17 1997-12-02 Roche Molecular Systems, Inc. Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions
US5561058A (en) 1986-08-22 1996-10-01 Hoffmann-La Roche Inc. Methods for coupled high temperatures reverse transcription and polymerase chain reactions
IE72468B1 (en) 1987-07-31 1997-04-09 Univ Leland Stanford Junior Selective amplification of target polynucleotide sequences
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
DE68928853T2 (de) 1988-05-20 1999-08-05 Cetus Corp Befestigung von sequenzspezifischen proben
US5639611A (en) 1988-12-12 1997-06-17 City Of Hope Allele specific polymerase chain reaction
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5137806A (en) 1989-12-11 1992-08-11 Board Of Regents, The University Of Texas System Methods and compositions for the detection of sequences in selected DNA molecules
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
EP0487218B1 (en) 1990-10-31 1997-12-29 Tosoh Corporation Method for detecting or quantifying target nucleic acid
ZA918965B (en) 1990-11-13 1992-08-26 Siska Diagnostics Inc Nucleic acid amplification by two-enzyme,self-sustained sequence replication
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5994056A (en) 1991-05-02 1999-11-30 Roche Molecular Systems, Inc. Homogeneous methods for nucleic acid amplification and detection
CA2081582A1 (en) 1991-11-05 1993-05-06 Teodorica Bugawan Methods and reagents for hla class i dna typing
JP2001507921A (ja) 1992-04-27 2001-06-19 トラスティーズ オブ ダートマス カレッジ 生物学的液体中の遺伝子配列の検出
JPH09507121A (ja) 1993-10-26 1997-07-22 アフィマックス テクノロジーズ ナームロゼ ベノートスハップ 生物学的チップ上の核酸プローブアレー
US5491063A (en) 1994-09-01 1996-02-13 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
US5571673A (en) 1994-11-23 1996-11-05 Hoffmann-La Roche Inc. Methods for in-solution quenching of fluorescently labeled oligonucleotide probes
WO2008128233A1 (en) * 2007-04-15 2008-10-23 University Of Chicago Methods and compositions concerning the vegfr-2 gene (kinase domain receptor, kdr)
EP2506010B1 (en) * 2007-11-30 2015-06-17 Genentech, Inc. VEGF polymorphisms and anti-angiogenesis therapy
WO2010124264A2 (en) * 2009-04-24 2010-10-28 University Of Southern California Genetic variants in angiogenesis pathway associated with clinical outcome
US20120108441A1 (en) * 2009-04-24 2012-05-03 University Of Southern California Polymorphisms in angiogenesis pathway genes associated with tumor recurrence in surgery treated cancer patients

Also Published As

Publication number Publication date
KR20140064924A (ko) 2014-05-28
EP2751280B1 (en) 2016-06-29
US20140294811A1 (en) 2014-10-02
AR087714A1 (es) 2014-04-09
IL230783A0 (en) 2014-03-31
RU2014110270A (ru) 2015-10-10
JP2014526901A (ja) 2014-10-09
NZ620343A (en) 2016-10-28
SG2014008585A (en) 2014-04-28
EP2751280A1 (en) 2014-07-09
BR112014004763A2 (pt) 2017-03-21
WO2013030168A1 (en) 2013-03-07
CN103946395A (zh) 2014-07-23
EP3085793A1 (en) 2016-10-26
ES2589455T3 (es) 2016-11-14
CA2845386A1 (en) 2013-03-07
AU2012300986A1 (en) 2014-02-13
ZA201400950B (en) 2015-08-26

Similar Documents

Publication Publication Date Title
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
MX2015004610A (es) Metodo para diagnostico, pronostico y tratamiento de metastasis de cancer de prostata usando c-maf.
UA115034C2 (uk) Імунокон'югат для застосування в лікуванні раку або запального порушення
WO2013153458A3 (en) Method for the prognosis and treatment of cancer metastasis
TR201819564T4 (tr) Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
MX2013002084A (es) Biomarcadores y metodos de tratamiento.
UA115540C2 (uk) Антитіло до il-36r
MX2014006404A (es) Metodos y kits para el pronostico del cancer colorrectal.
MX2019000091A (es) Metodo para el pronostico y tratamiento de cancer metastasico de los huesos originado de cancer de mama.
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
EA201590747A1 (ru) Способы лечения с использованием аденовируса
MX344315B (es) Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama.
WO2011146568A8 (en) Predicting response to a her inhibitor
MX2017013074A (es) Metodos y composiciones para prediccion de eficacia terapeutica de tratamientos contra el cancer y prognosis del cancer.
WO2011122857A3 (ko) 유방암 예후 예측을 위한 조성물 및 이를 포함하는 키트
MX2017015922A (es) Biomarcadores asociados con inhibidores de lsd1 y usos de los mismos.
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
PH12015500388A1 (en) Cancer diagnostic and therapeutic method targeting molecules expressed in cancer stem cells
WO2012109233A3 (en) Methods for predicting recurrence risk in breast cancer patients
MX2014001736A (es) Inhibicion de angiogenesis en tumores refractarios.
AU2012342682A8 (en) Responsiveness to angiogenesis inhibitors
WO2015036643A3 (es) Marcador para predecir metástasis del cáncer de mama
MX2014002307A (es) Metodo para predecir el riesgo de hipertension asociado a la terapia antiangiogenesis.
EA201490201A1 (ru) Выявление экспрессии гена prame при раковом заболевании